Tech Center 1600 • Art Units: 1617 1622 1627
This examiner grants 65% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18101220 | ANTIFUNGAL PROPHYLAXIS FOR CORNEA | Non-Final OA | PRESIDENT AND FELLOWS OF HARVARD COLLEGE |
| 18212720 | Medical Treatments Based on Anamorelin | Non-Final OA | Helsinn Healthcare SA |
| 18055045 | USE OF JUMONJI C DEMETHYLASE INHIBITORS FOR THE TREATMENT AND PREVENTION OF CHEMOTHERAPY RESISTANCE AND RADIORESISTANCE IN CANCER | Final Rejection | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM |
| 17878121 | USE OF RILUZOLE, RILUZOLE PRODRUGS OR RILUZOLE ANALOGS WITH IMMUNOTHERAPIES TO TREAT CANCERS | Final Rejection | Biohaven Therapeutics Ltd. |
| 18470859 | SURFACTANT BLENDS FOR HYPOHALITE-BASED DISINFECTING COMPOSITIONS | Non-Final OA | GOJO Industries, Inc. |
| 18477467 | PHARMACEUTICAL COMPOSITION COMPRISING A CANNABINOID | Non-Final OA | Jazz Pharmaceuticals Research UK Limited |
| 18446405 | CANNABIDIOL PREPARATIONS AND ITS USES | Non-Final OA | Jazz Pharmaceuticals Research UK Limited |
| 18005868 | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH CHRNA4 MUTATION | Non-Final OA | Jazz Pharmaceuticals Research UK Limited |
| 17665969 | Methods for Treatment of Fabry Disease | Final Rejection | Amicus Therapeutics, Inc. |
| 18466051 | METHODS OF TREATING OR PREVENTING A PROTEOPATHY | Non-Final OA | Usher III Initiative, Inc. |
| 18005959 | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | Non-Final OA | GW Research Limited |
| 18273813 | NOVEL CRYSTALLINE COMPOUND OF SIPONIMOD HEMIFUMARATE | Non-Final OA | OLON S.P.A. |
| 18273433 | Cyclic Glycoaminoacid Derivatives | Non-Final OA | TFCHEM |
| 18219105 | METHODS FOR EXTENDING LIFESPAN AND/OR DELAYING AGING | Non-Final OA | Chang Gung University |
| 18015096 | PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | Final Rejection | SHANGHAI RAISING PHARMACEUTICAL CO., LTD. |
| 17443650 | METHODS OF TREATING CIRCADIAN RHYTHM SLEEP DISORDERS | Final Rejection | Eisai R&D Management Co., Ltd. |
| 18032918 | Bicyclic Compounds and Uses Thereof for the Treatment of Diseases | Non-Final OA | Athira Pharma, Inc. |
| 18015790 | COMPOSITION COMPRISING CANNABINOIDS, TERPENES, AND FLAVONOIDS FOR TREATING DEPRESSION | Non-Final OA | YIRMIYA, RAZ |
| 18085792 | THERAPEUTIC COMPOSITIONS, COMBINATIONS, AND METHODS OF USE | Non-Final OA | Verastem, Inc. |
| 17784682 | COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATION WITH STEROIDS AND A MODULATOR | Non-Final OA | BUZZELET DEVELOPMENT AND TECHNOLOGIES LTD. |
| 17879923 | 6-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME | Non-Final OA | Trevena, Inc. |
| 17775260 | TREATMENT AND PREVENTION OF NEUROINFLAMMATION OR AN INFLAMMATORY BRAIN DISORDER | Final Rejection | Inflazome Limited |
| 17302781 | METHODS FOR TREATING HAIR LOSS AND COMPOSITIONS FOR SAME | Non-Final OA | Chemistry RX |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy